Notable Upgrades: Amazon.com (AMZN), VMware (VMW), Valeant Pharma (VRX), Las Vegas Sands (LVS)

Amazon.com, Inc. (AMZN) was reiterated a ‘Buy’ by Axiom Capital analysts on Tuesday. The broker also raised its price target on the stock to $727 from $650, noting the e-commerce giant could very well embark on another aggressive spending cycle that could again test investor’s patience.

AMZN is currently printing a normal trading volume with the issue trading 1.99 million shares, compared to the average daily volume of 4.26 million. The stock began trading this morning at $608.60 to currently trade 0.66% higher from the prior days close of $608.61. On an intraday basis it has gotten as low as $605.53 and as high as $614.45.

Amazon.com Inc. shares are priced at 877.65x this year’s forecasted earnings, compared to the industry’s 17.98x earnings multiple. The company’s current year and next year EPS growth estimates stand at 455.80% and 190.30%, compared to the industry growth rates of 10.00% and 19.50%, respectively. AMZN has a t-12 price-to-sales ratio of 2.84. EPS for the same period registers at $0.70.

Amazon.com Inc. is up 112.01% year-over-year, compared with a 5.58% gain in the S&P 500.

Analysts at Drexel Hamilton upgraded their rating on the shares of VMware, Inc. (VMW). In a research note published on Tuesday, the firm lifted the name with a ‘Buy’ from ‘Hold’ rating as they like the valuation here.

VMware Inc. shares are currently priced at 26.85x this year’s forecasted earnings, compared to the industry’s 10.30x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.01 and 14.15, respectively. Price/Sales for the same period is 3.89 while EPS is $2.21. Currently there are 10 analysts that rate VMW a ‘Buy’, 24 rate it a ‘Hold’. One analyst rates it a ‘Sell’.

VMW has a median Wall Street price target of $75 with a high target of $119.

Valeant Pharmaceuticals (VRX) was raised to ‘Buy’ from ‘Neutral’ with $155 target at Mizuho on Tuesday. Firm believes VRX could be subject to more negative media coverage as they await the results of its internal audit ; they think the name could be more resilient going forward even if the Street lowers estimates.

In a report published Tuesday, Gabelli & Co analysts initiated coverage on Las Vegas Sands Corp. (LVS) with a ‘Buy’ rating and $60 price target.

On valuation measures, Las Vegas Sands Corp. shares currently have a PEG and forward P/E ratio of 3.34 and 18.34, respectively. Price/sales for the same period is 3.18 while EPS is $2.78. Currently there are 9 analysts that rate LVS a ‘Buy’, 9 rate it a ‘Hold’. No analyst rates it a ‘Sell’.

LVS has a median Wall Street price target of $53 with a high target of $63.

In the past 52 weeks, shares of Las Vegas, Nevada-based company have traded between a low of $36.53 and a high of $65.35 and are now at $47.27.

Shares are down 18.43% year-over-year and 12.79% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*